T. Rowe Price Investment Management’s Structure Therapeutics GPCR Stock Holding History

T. Rowe Price Investment Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-715,968	Closed	-$31.4M	–	651
2024 Q3	$31.4M	Buy	715,968 +19,470	+3%	+$753K	0.02%	473
2024 Q2	$27.4M	Sell	696,498 -519,805	-43%	-$21.3M	0.02%	472
2024 Q1	$52.1M	Sell	1,216,303 -95,892	-7%	-$4.04M	0.03%	390
2023 Q4	$53.5M	Sell	1,312,195 -259,482	-17%	-$14.9M	0.03%	386
2023 Q3	$79.2M	Buy	1,571,677 +917,161	+140%	+$29.6M	0.06%	289
2023 Q2	$27.2M	Buy	654,516 +56,408	+9%	+$1.58M	0.02%	449
2023 Q1	$14.2M	Buy	+598,108	New	+$14.1M	0.01%	495

Other funds holding GPCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management's GPCR Position: Q4 2024 in Review

T. Rowe Price Investment Management sold out of Structure Therapeutics (GPCR) in Q4 2024, closing a stake of 715,968 shares — an estimated $31.4M sold.

T. Rowe Price Investment Management first reported a position in GPCR in Q1 2023 and held it in 7 quarters. The position peaked at $79.2M in Q3 2023. 164 funds tracked by Wall St. Rank hold GPCR as of Q4 2024.

T. Rowe Price Investment Management reported no remaining Structure Therapeutics position as of Q4 2024 after selling out during the quarter.
T. Rowe Price Investment Management sold 715,968 Structure Therapeutics shares in Q4 2024, an estimated $31.4M.
T. Rowe Price Investment Management first reported a position in Structure Therapeutics in Q1 2023 and held it in 7 quarters.
T. Rowe Price Investment Management's Structure Therapeutics position peaked at $79.2M in Q3 2023.
164 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2024.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.